🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re excited for today's launch as we advance the next wave of medicine for allergy & inflammation. Our lead candidate, THB001, is the 1st oral KIT inhibitor in clinical development for mast cell-driven allergic & inflammatory diseases. Read our release: thirdharmonicbio.com

I had a patient in clinic the other day in misery with severe, disfiguring hives. H1 blockers weren't working. Xolair incredibly difficult to take. Wouldn't it be nice to have a pill that worked better? Good luck, 3HB! endpts.com/audentes-old-c…

Excited by today’s launch of Third Harmonic Bio! We look forward to bringing the next wave of medicine to patients suffering from mast cell-mediated allergy & inflammation.

#Biotech News: As we expand our operations to include the U.S., we're thrilled to welcome Howard E. Davis, Ph.D., as our new CEO. Dr. Davis is uniquely positioned to lead us through our next phase of growth. psioxus.com/news #cancer #immunooncology #leadership #biotech

We have a new name, fit for a warrior. PsiOxus Therapeutics is now Akamis Bio! Today we also announced a $30M convertible note financing led by ARCH Venture Partners, Parker Institute for Cancer Immunotherapy & WestlakeVillageBioPartners that will further leverage our T-SIGn® tumor #genetherapy platform. #solidtumors

Seeing all of these faces at the 41st Annual J.P. Morgan Healthcare Conference 2023 in San Francisco is wonderful. #JPM2023 We're enjoying the great discussions while sharing our latest news that's helping us pave the way to a better future in #cancer care. jpmorgan.com/solutions/cib/…

Thrilled to announce the completion of Akamis Bio’s Series A Prime financing and new strategic partnership which provide funding to support the advancement of our lead oncology candidate, NG-350A, into a clinical proof-of-concept study in patients with locally advanced rectal

RT if you are FOR the motion:The only way is Pharma: Academic trials go nowhere #burningdebate ACTRIMS® ECTRIMS #MSboston2014